Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This clinical trial is studying how well erlotinib works in treating patients with stage
IIIB, stage IV, or recurrent non-small cell lung cancer. Erlotinib may stop the growth of
tumor cells by blocking the enzymes necessary for their growth.